Search Results
LOXO-35: a next gen BTK inhibitor for B-cell malignancies
BRUIN trial: LOXO-305 for B-cell malignancies
Targeting BTK in B-Cell Malignancies
Anthony Mato: LOXO-305 Demonstrates Efficacy in Patients With CLL/SLL
LOXO-305 as a novel treatment in previously treated NHL: results from the BRUIN trial
MCL: Differences in Trial Design Between BTK Inhibitors
Novel BTK Inhibitors: Overcoming Intolerance, Resistance, and Other Challenges in B-Cell Cancers
New data about BTK inhibitors in NHL
ASH 2020 Chronic Lymphocytic Leukemia Expert Roundtable Episode 3 of 4 - Medpage Today
BTK Inhibitors as a Centerpiece of Care for Hematologic Cancers
LOXO-338 for the treatment of advanced hematological malignancies
BTK inhibitors - Wang
